Alkermes plc (ALKS)
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ALKS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.95B
- P/E (TTM)
- 109.07
- Forward P/E
- 22.92
- EPS (TTM)
- $0.38
- Dividend yield
- None
- 52-week range
- 27.00 – 55.67
- Day range
- 41.17 – 42.06
- Volume / Avg
- 1.76M / 1.83M
- Beta
- —
- Shares outstanding
- 167.76M
- Next earnings
- Oct 27, 2026
52-week range
ALKS stock today
On Oct 7, ALKS ended the session at $41.45, shedding $0.205 (0.49%), versus the S&P 500's 0.22% decline. Shares are 25.6% below their 52-week high of $55.67, set on Jul 7, 2026 and 53.5% above the 52-week low of $27.00, in the middle of the past year's range. ALKS is up 48.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 33.9%.
Alkermes trades at 109.1x its trailing twelve-month earnings per share of $0.38. Its forward P/E of 22.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of -$0.08.
Summary generated from market data by MetaCap's automated system. Methodology
About Alkermes
Company profileAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Blair C. Jackson
- Headquarters
- Dublin
- Employees
- 2,050
- IPO year
- 1991
- Website
- alkermes.com
Financial highlights
Full financialsIn fiscal 2025, Alkermes generated $1.48 billion in revenue, down 5.2% from fiscal 2024, its first annual decline since 2024. Net income was $241.7 million (-34.2% year over year), for a net margin of 16.4% versus a median of -4.1% in the prior 5 years. Gross margin was 86.7% (up from 84.2%) and operating margin 17.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Growth | -5.25% | -6.36% | +49.61% | -5.28% | +13.00% |
| Net income | $241.66M | $367.07M | $355.76M | $-158.27M | $-48.17M |
| EPS (diluted) | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 |
Analyst forecast
ForecastConsensus (19 analysts)
buy
Avg. price target
$56.56+36.47%
- Strong buy 3
- Buy 11
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $-0.08
- Last reported (Q2 2026)
- Jul 28, 2026
- EPS actual vs est.
- $0.00 vs —
Alkermes peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs ALKS |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | -3.18% | $6.84B | vs ALKS |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs ALKS |
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs ALKS |
| BLTEBelite Bio Inc ADR | 156.08 | +0.30% | $6.29B | vs ALKS |
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs ALKS |
| RYTMRhythm Pharmaceuticals Inc. | 88.45 | -2.56% | $6.09B | vs ALKS |
| KNSAKiniksa Pharmaceuticals International plc Class A | 77.96 | +1.13% | $6.08B | vs ALKS |
Indexes, lists and sector
Alkermes stock FAQ
What is Alkermes's stock price today?
ALKS last traded at $41.45 as of Oct 7, 4:00 PM EDT, down 0.49% on the day. Prices are delayed at least 15 minutes.
Does Alkermes pay a dividend?
No. Alkermes does not currently pay a regular cash dividend.
When is Alkermes's next earnings date?
Alkermes is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $-0.08.
What is ALKS's P/E ratio?
ALKS trades at a trailing P/E ratio of 109.07 and a forward P/E of 22.92.
Who is Alkermes's CEO?
Mr. Blair C. Jackson is the chief executive officer of Alkermes plc, which has about 2,050 employees.
Has ALKS ever split its stock?
Yes. The most recent ALKS stock split was a 2-for-1 split on May 15, 2000.
What is the ALKS 52-week high?
The 52-week high for ALKS is $55.67 and the 52-week low is $27.00. The stock is currently 25.6% below its high.